UPDATE: Jefferies Reiterates Buy Rating, Raises PT on Pacira Pharmaceuticals on Strong Momentum

In a report published Friday, Jefferies reiterated its Buy rating on Pacira Pharmaceuticals (NASDAQ: PCRX ), and raised its price target from $24.00 to $32.00. Jefferies noted, “PCRX is heading into its 4th Q of Exparel launch with strong momentum. Exparel access and uptake continue to ramp (volume growth through